Scientists Are Getting Closer to Reversing Inherited Blindness—Here's What That Means

A groundbreaking gene therapy approach is showing remarkable promise for treating inherited blindness, with researchers successfully restoring vision in mouse models for over a year using a single injection. Scientists at West Virginia University (WVU) are pioneering this treatment for people who lose their sight due to mutations in the PROM1 gene, offering hope where no treatment currently exists.

What Causes This Type of Inherited Blindness?

The research focuses on mutations in the Prominin1, or PROM1 gene, which produces a protein found throughout the body. When this gene doesn't work properly, it disrupts normal vision. Scientists have identified approximately 50 distinct PROM1 mutations that can cause vision loss, yet until now, there's been no way to treat or reverse the blindness they cause.

"We see patients at the WVU Eye Institute who carry these mutations, and right now there is no treatment to stop or reverse their vision loss," said Visvanathan Ramamurthy, professor and chair of the Department of Biochemistry and Molecular Medicine at WVU School of Medicine.

How Does the Gene Therapy Work?

The treatment involves delivering healthy genetic material directly into the back of the eye using a harmless viral vector—essentially a modified virus that can't cause disease but can carry therapeutic genes to the right cells. Working with medical student George Holmes and postdoctoral researcher Sila Niedoba, Ramamurthy's team has achieved encouraging results in their mouse studies.

The therapy's effectiveness extends beyond just preventing further vision loss. The research team has observed that their approach can actually restore vision that was already lost, with benefits lasting at least a year in mouse models. "That one-year window in mice is significant," Ramamurthy explained. "It suggests the potential for a much longer period of effectiveness when translated to human patients."

What Makes This Research Different?

Unlike treatments that only work in the earliest stages of disease, this gene therapy shows promise even after vision loss has progressed. This is crucial because most patients don't seek treatment immediately when symptoms first appear. The research team is specifically investigating whether the therapy remains effective in middle or later stages of the disease.

The study is supported by a three-year $1.4 million grant from the National Eye Institute, part of the National Institutes of Health. The research involves several key areas of investigation:

• Delivery Method: Using harmless viral vectors to transport functional genetic material directly to retinal cells
• Timing Effectiveness: Testing whether treatment works at different stages of disease progression, not just early onset
• Duration of Benefits: Measuring how long the therapeutic effects last after a single injection
• Clinical Translation: Preparing the research for eventual human trials at the expanded WVU Eye Institute

The timing of this research aligns with WVU's planned expansion of their Eye Institute, scheduled for completion in late 2027. This new infrastructure is expected to provide the necessary facilities to translate these laboratory successes into human clinical trials.

"Our lab has studied inherited blindness for nearly 20 years," Ramamurthy said. "Now, our focus is on translating these laboratory successes into clinical realities for our patients." The research represents a significant step forward in ophthalmology, particularly for treating genetic eye diseases that currently have no therapeutic options.